Abstract
Drug hypersensitivity reactions (DHRs) are adverse drug reactions that may be divided into several categories; namely pharmacologic intolerance, idiosyncratic reactions, pseudo-allergic reactions and allergic reactions. Drug allergic reactions are those DHRs that are mediated by either antibodies or drug-specific T cells. They vary in terms of severity, time-to-onset of clinical manifestations and target organ. Skin is most commonly implicated in drug hypersensitivity reactions; however, it is now apparent that reactions targeting internal organs fall under the definition of drug hypersensitivity. Multiple hypotheses have been proposed to explain the diverse immune mechanisms involved and the heterogeneous clinical presentation. The discovery of human leukocyte antigen (HLA) risk alleles for some DHRs has provided insights in the pathogenesis of these reactions. In this review we summarize immune cells involved in DHRs, discuss the possible immunological mechanisms of DHRs, with an emphasis on the IgE-mediated immediate reactions and T cell-dependent delayed type reactions.
Keywords: Drug hypersensitivity, T-cells, IgE.
Current Pharmaceutical Design
Title:Immunological Mechanisms of Drug Hypersensitivity
Volume: 22 Issue: 45
Author(s): Xiaoli Meng, Adriana Ariza, James Waddington, Kevin Park and Dean Naisbitt
Affiliation:
Keywords: Drug hypersensitivity, T-cells, IgE.
Abstract: Drug hypersensitivity reactions (DHRs) are adverse drug reactions that may be divided into several categories; namely pharmacologic intolerance, idiosyncratic reactions, pseudo-allergic reactions and allergic reactions. Drug allergic reactions are those DHRs that are mediated by either antibodies or drug-specific T cells. They vary in terms of severity, time-to-onset of clinical manifestations and target organ. Skin is most commonly implicated in drug hypersensitivity reactions; however, it is now apparent that reactions targeting internal organs fall under the definition of drug hypersensitivity. Multiple hypotheses have been proposed to explain the diverse immune mechanisms involved and the heterogeneous clinical presentation. The discovery of human leukocyte antigen (HLA) risk alleles for some DHRs has provided insights in the pathogenesis of these reactions. In this review we summarize immune cells involved in DHRs, discuss the possible immunological mechanisms of DHRs, with an emphasis on the IgE-mediated immediate reactions and T cell-dependent delayed type reactions.
Export Options
About this article
Cite this article as:
Meng Xiaoli, Ariza Adriana, Waddington James, Park Kevin and Naisbitt Dean, Immunological Mechanisms of Drug Hypersensitivity, Current Pharmaceutical Design 2016; 22 (45) . https://dx.doi.org/10.2174/1381612822666161003115103
DOI https://dx.doi.org/10.2174/1381612822666161003115103 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Recent Patents on Inflammation & Allergy Drug Discovery Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation as Potential Alzheimers Therapies
Current Bioactive Compounds Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma
Current Cancer Drug Targets The Trinity of Matrix Metalloproteinases, Inflammation, and Cancer: A Literature Review of Recent Updates
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Blood Stem Cells and non-Hematological Clinical Practice: Pragmatics Before Therapeutics
Current Pharmaceutical Biotechnology S100A8/A9 Proteins in Diseases of the Exocrine Pancreas
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-Angiogenic Approaches to Malignant Gliomas
Current Cancer Drug Targets Depression in Older Persons with Mobility Limitations
Current Pharmaceutical Design The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design The Effect of Proteinuria on Antinuclear Antibody Assay Results in Patients with Glomerulonephritis
Applied Clinical Research, Clinical Trials and Regulatory Affairs Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor
Current Pharmaceutical Design Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets The Role of Virulence Factors in the Pathogenicity of Colletotrichum sp.
Current Protein & Peptide Science Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Organ Culture Bioreactors – Platforms to Study Human Intervertebral Disc Degeneration and Regenerative Therapy
Current Stem Cell Research & Therapy Presentation of Neuroendocrine Self in the Thymus: Toward a Novel Type of Vaccine / Immunotherapy
Drug Design Reviews - Online (Discontinued)